Pep2m, Myristoylated (TFA)

About the Target

Pep2m, myristoylated (TFA) is a cell-permeable peptide, which can disrupt the protein kinase ζ (PKMζ) downstream targets, N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions. The mapped biological anchor for this entry is PKM-zeta / NSF / GluR2 interaction axis (PRKCZ, NSF, and GRIA2), although the description suggests that interpretation should remain at fragment, family, or pathway level. The mapped biology is best interpreted at pathway or interactome level, where the peptide is used to bias a response without assuming that every downstream change reflects exclusive engagement of one molecular species. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. This framing is especially useful when investigators want to perturb a defined signaling interface without assuming that all downstream changes arise from one molecular node.

Research Context

As an interaction disruptor, it is most informative when paired with assays that directly measure complex formation, localization, or rescue of downstream signaling. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.

• pair treatment with orthogonal pathway biomarkers whenever direct target engagement cannot be assumed
• use dose-response and time-course designs to connect early pathway shifts with later phenotypic outcomes
• frame conclusions at network level when more than one molecular node may contribute to the effect

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

For routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, keeping the listed tfa; myristoylated format constant across comparator groups can reduce avoidable formulation-related differences. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.